TY  - GEN
AU  - Du,Lanying
AU  - Li,Fang
TI  - MERS-CoV
SN  - books978-3-03921-851-6
PY  - 2019///
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - cell–cell fusion
KW  - hDPP4
KW  - n/a
KW  - therapeutics
KW  - animal models
KW  - HCoV-229E
KW  - Drivers
KW  - camels
KW  - rabbits
KW  - SARS-CoV
KW  - MERS-CoV
KW  - MVA vaccine
KW  - transmission
KW  - RBD
KW  - MERS-CoV nucleocapsid protein
KW  - complement
KW  - animal model
KW  - pseudotyped virus
KW  - combination
KW  - MERS-coronavirus
KW  - peptide
KW  - mouse model
KW  - spike protein
KW  - receptor-binding domain
KW  - prevention and treatment
KW  - coronaviruses
KW  - coronavirus spike glycoprotein
KW  - therapeutic antibodies
KW  - vaccine platforms
KW  - mutation
KW  - severe acute respiratory syndrome coronavirus
KW  - pathogenesis
KW  - fusion inhibitor
KW  - Coronavirus
KW  - murine CD8+ T cell epitope
KW  - lipidomics
KW  - authentic virus
KW  - correlates of immunity
KW  - vaccines
KW  - neutralizing monoclonal antibodies
KW  - Middle East respiratory syndrome coronavirus
KW  - small-molecule inhibitor
KW  - Middle East Respiratory Syndrome Virus
KW  - DPP4
KW  - pyroptosis
KW  - cross-neutralization
KW  - inflammation
KW  - Qatar
KW  - spike proteins
KW  - One Health
KW  - HKU4
KW  - nanobodies
KW  - mechanism of action
KW  - neutralizing antibody
KW  - host factors
KW  - UHPLC–MS
N1  - Open Access
N2  - Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic coronavirus. First identified in 2012, MERS-CoV has caused over 2460 infections and a fatality rate of about 35% in humans. Similar to severe acute respiratory syndrome coronavirus (SARS-CoV), MERS-CoV likely originated from bats; however, different from SARS-CoV, which potentially utilized palm civets as its intermediate hosts, MERS-CoV likely transmits to humans through dromedary camels. Animal models, such as humanized mice and nonhuman primates, have been developed for studying MERS-CoV infection. Currently, there are no vaccines and therapeutics approved for the prevention and treatment of MERS-CoV infection, although a number of them have been developed preclinically or tested clinically. This book covers one editorial and 16 articles (including seven review articles and nine original research papers) written by researchers working in the field of MERS-CoV. It describes the following three main aspects: (1) MERS-CoV epidemiology, transmission, and pathogenesis; (2) current progress on MERS-CoV animal models, vaccines, and therapeutics; and (3) challenges and future prospects for MERS-CoV research. Overall, this book will help researchers in the MERS-CoV field to further advance their work on the virus. It also has important implications for other coronaviruses as well as viruses outside the coronavirus family with pandemic potentials
UR  - https://mdpi.com/books/pdfview/book/1893
UR  - https://directory.doabooks.org/handle/20.500.12854/53201
ER  -